MedTrace Logo

Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery

NCT02552459 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2016-10-18

No results posted yet for this study

Summary

The purpose of this study is to determine effect of combined medication of sufentanil and dexmedetomidine in patient controlled analgesia after neurosurgery.

Conditions

  • Arteriovenous Malformation

Interventions

DRUG

Sufentanil

sufentanil 150μg， intravenous administration during post-operative 72 hours.

DRUG

dexmedetomidine 1

dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation

DRUG

dexmedetomidine 2

dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation

DRUG

dexmedetomidine 3

dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Jiang Nan, doctor · The First Affiliated Hospital, Sun Yat-sen Unniversity

  • Shao Xinxin, master · The First Affiliated Hospital, Sun Yat-sen Unniversity

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02552459 on ClinicalTrials.gov